Last updated: September 9, 2026
Nirogacestat hydrobromide, marketed as Ogsiveo by SpringWorks Therapeutics, is the first FDA-approved systemic therapy specifically indicated for adults with progressing desmoid tumors requiring systemic treatment. The product has orphan-drug protection through November 2030, limited direct competition, and a premium specialty-pharmaceutical pricing model. Its principal risks are the small addressable population, chronic tolerability issues, payer controls, and reliance on a single commercial product.
SpringWorks reported rapid initial adoption after the November 2023 launch. Ogsiveo revenue moved from launch-period sales in 2023 to more than $200 million in 2024, establishing nirogacestat as the company’s primary commercial asset. The longer-term opportunity depends on geographic expansion, earlier-line use, additional indications, and the company’s ability to defend formulation, method-of-use, and regulatory exclusivity beyond the core orphan period.
What is nirogacestat hydrobromide and how is Ogsiveo used?
Nirogacestat is an oral, selective gamma-secretase inhibitor. Gamma-secretase inhibition reduces Notch signaling, a pathway implicated in desmoid tumor growth. Ogsiveo is administered at 150 mg twice daily for adults with progressing desmoid tumors requiring systemic treatment. The FDA approved the drug on November 27, 2023, under the accelerated approval pathway based on objective response data from the DeFi Phase 3 trial.[1]
The approved indication is narrow:
| Item |
Nirogacestat hydrobromide |
| Brand |
Ogsiveo |
| Active ingredient |
Nirogacestat hydrobromide |
| Sponsor at approval |
SpringWorks Therapeutics |
| FDA application |
NDA 214954 |
| Dosage form |
Oral tablets |
| Strength |
50 mg, 100 mg, 150 mg |
| Approved indication |
Adults with progressing desmoid tumors requiring systemic treatment |
| FDA approval date |
November 27, 2023 |
| Regulatory pathway |
Accelerated approval |
| Orphan-drug exclusivity |
Expected through November 27, 2030 |
| Key trial |
DeFi, Phase 3 |
| Primary commercial risk |
Small patient population and chronic adverse events |
The main adverse events include diarrhea, ovarian toxicity, rash, nausea, fatigue, and laboratory abnormalities. Ovarian dysfunction is a material commercial and prescribing consideration for women of reproductive potential. The label includes monitoring and reproductive-risk provisions that can limit treatment persistence.[1]
How large is the nirogacestat market?
The addressable U.S. market is small in patient count but high in annual treatment value. Desmoid tumors are rare, locally aggressive, nonmetastatic tumors. Estimates of incidence vary, but the total U.S. prevalence is generally measured in the low tens of thousands, with only a subset having progressive disease requiring systemic treatment.
The commercial market has several favorable characteristics:
- No FDA-approved systemic competitor had the same indication at Ogsiveo’s launch.
- Patients often cycle through surgery, radiation, chemotherapy, tyrosine kinase inhibitors, or off-label agents.
- Treatment can be chronic rather than limited to a short induction course.
- The disease is managed in specialized oncology centers, allowing focused sales coverage.
- Orphan status supports premium pricing and reimbursement leverage.
The market is constrained by the fact that many desmoid tumors are initially managed with active surveillance. Ogsiveo is not indicated for every diagnosed patient. Use generally requires documented progression and a clinical judgment that systemic treatment is necessary.
How does nirogacestat compare with competing desmoid-tumor therapies?
| Therapy |
Status in desmoid tumors |
Commercial position |
| Nirogacestat |
FDA-approved systemic therapy |
Premium branded standard for eligible progressing adults |
| Sorafenib |
Off-label or guideline-supported systemic option |
Lower-cost generic competition |
| Pazopanib |
Off-label systemic option |
Generic, with tolerability and reimbursement variability |
| Liposomal doxorubicin |
Chemotherapy option |
Infusion-based and more toxic |
| Methotrexate/vinblastine |
Chemotherapy option |
Long treatment courses and monitoring burden |
| Surgery |
Local treatment |
Recurrence and morbidity concerns |
| Radiation |
Local treatment |
Limited by anatomic site and long-term toxicity |
| Watchful waiting |
Common initial strategy |
No drug cost, but unsuitable for progression requiring treatment |
Nirogacestat’s competitive advantage is regulatory status and disease-specific evidence. Its pricing advantage is weaker against generic sorafenib, pazopanib, and chemotherapy, particularly when payers require step therapy.
What is the revenue trajectory for Ogsiveo?
Ogsiveo moved quickly from launch to a meaningful commercial contribution. SpringWorks’ 2024 filings identified Ogsiveo product revenue as the company’s core revenue stream and reported strong prescription growth during the first full year of commercialization.[2]
| Period |
Commercial status |
Revenue interpretation |
| 2023 |
U.S. launch in late November |
Limited launch-quarter revenue |
| 2024 |
First full commercial year |
More than $200 million in annual product revenue, based on company reporting |
| 2025 onward |
Expansion and penetration phase |
Growth depends on patient identification, persistence, international access, and label expansion |
The revenue curve has the typical orphan-oncology pattern: rapid initial uptake among concentrated high-need patients, followed by a slower phase driven by broader diagnosis, payer access, treatment duration, and physician familiarity.
Key financial drivers include:
- New patient starts. Early growth depends on identifying patients with documented progression.
- Treatment persistence. Chronic administration supports recurring revenue, but diarrhea and ovarian toxicity can cause interruptions or discontinuation.
- Net pricing. Gross list price is reduced by commercial rebates, government discounts, patient assistance, and distribution costs.
- International launch timing. Regulatory approvals outside the United States can materially expand the opportunity.
- Indication expansion. Additional Notch-driven tumors could change the scale of the asset.
The principal downside is concentration. Ogsiveo represented the commercial foundation of SpringWorks, so any safety signal, reimbursement restriction, manufacturing disruption, or competitive clinical result would have an outsized impact on corporate results.
When does nirogacestat lose exclusivity?
The most important near-term protection is FDA orphan-drug exclusivity, which is expected to run for seven years from approval, through November 27, 2030. Orphan exclusivity prevents FDA approval of the same drug for the same disease or condition during that period, subject to statutory exceptions.[3]
Orphan exclusivity does not prevent every form of competition. It does not block:
- A different active ingredient with the same indication.
- An alternative formulation that qualifies as a different product.
- Off-label use of generic therapies.
- Competing drugs approved through other regulatory pathways.
- Certain applications based on clinical superiority or drug shortages.
- Patent challenges that do not result in FDA approval during the exclusivity period.
Small-molecule patent protection may extend beyond 2030, depending on the Orange Book-listed patents, patent-term adjustment, patent-term extension, pediatric exclusivity, and any successful litigation or settlement. The commercial loss-of-exclusivity date therefore should not be equated with the expiration of orphan exclusivity.
What patents protect Ogsiveo?
Ogsiveo’s protection is expected to include a combination of:
- Active-ingredient or chemical-entity patents.
- Salt and solid-state patents covering nirogacestat hydrobromide.
- Pharmaceutical-composition patents.
- Tablet or dosage-form patents.
- Method-of-use patents covering treatment of desmoid tumors.
- Dosing and toxicity-management claims.
- Regulatory exclusivities independent of patents.
The hydrobromide salt is commercially relevant because the approved product uses nirogacestat hydrobromide rather than the unmodified free base. Salt, polymorph, crystal-form, and formulation claims can create additional barriers, although their validity depends on disclosure, enablement, written description, obviousness, and claim scope.
The Orange Book is the controlling source for current FDA-listed patents and exclusivity entries. Patent families originating from earlier gamma-secretase inhibitor research may have earlier expiration dates, while later formulation or indication patents can extend protection into the 2030s. Any valuation should separate:
| Protection category |
Strategic role |
| Core compound patent |
Protects the active molecule |
| Hydrobromide or solid-state patent |
Limits salt and crystalline-form substitution |
| Formulation patent |
Protects tablet composition or drug release characteristics |
| Method-of-use patent |
Covers use in desmoid tumors or related conditions |
| Orphan exclusivity |
Blocks same-drug, same-condition approval |
| Pediatric exclusivity |
Can add six months if granted |
| Patent-term extension |
May restore part of regulatory review time |
Are there Paragraph IV challenges to Ogsiveo?
A Paragraph IV challenge would be the principal U.S. pathway for an ANDA applicant seeking approval before relevant patents expire. The applicant would assert that listed patents are invalid, unenforceable, or not infringed.
Publicly confirmed Paragraph IV litigation and settlement activity must be assessed against the current FDA Orange Book and federal court docket. The commercial probability of an early generic launch is presently moderated by three factors:
- Orphan exclusivity is expected to remain in force through 2030.
- Desmoid tumors represent a small generic opportunity relative to the cost of patent litigation.
- A generic applicant would need to address the listed product, formulation, and use claims, not merely demonstrate bioequivalence.
A Paragraph IV filing could still affect valuation before an actual launch. Notice-letter litigation may produce a 30-month FDA stay for an ANDA, depending on timing and statutory requirements.[4] A settlement could defer generic entry, authorize a controlled launch date, or leave certain method-of-use claims in place.
What is the FDA regulatory status of nirogacestat?
Nirogacestat received accelerated approval based on overall response rate and duration of response in the DeFi study. The FDA required confirmatory evidence to verify clinical benefit.[1]
The regulatory risks are manageable but material:
- Failure to confirm benefit could lead to label restrictions or withdrawal.
- Additional safety findings could affect treatment duration.
- Reproductive toxicity and ovarian dysfunction may limit use in younger patients.
- Postmarketing obligations can increase development costs.
- Any expanded indication would require additional clinical and regulatory investment.
The accelerated-approval framework increases the importance of confirmatory-trial execution. A favorable confirmatory outcome would support durable market access and strengthen payer confidence. A negative or delayed outcome would increase commercial risk even if the existing indication remains temporarily available.
Is nirogacestat exposed to biosimilar competition?
No. Nirogacestat is a chemically synthesized small molecule, not a biologic. Biosimilar competition under the Biologics Price Competition and Innovation Act is therefore not applicable. Competition would arise through the ANDA generic-drug pathway, branded small-molecule competitors, or off-label use of existing therapies.
This distinction improves the predictability of the eventual generic pathway. The central legal issues will be patent validity, infringement, formulation similarity, labeling carve-outs, and orphan exclusivity rather than biologic interchangeability.
Which companies challenge or compete with SpringWorks?
No single company has established a direct FDA-approved substitute with the same desmoid-tumor label. Competitive pressure comes from several groups:
- Generic manufacturers of sorafenib and pazopanib.
- Oncology companies developing targeted agents for desmoid tumors.
- Academic groups studying gamma-secretase inhibition and Notch signaling.
- Manufacturers of chemotherapy and local-treatment alternatives.
- Companies developing therapies for broader rare-tumor indications.
The strongest near-term competition is economic rather than directly pharmacologic. Generic TKIs can be used at substantially lower cost, and payers may require failure or intolerance before approving Ogsiveo.
What licensing deals affect nirogacestat?
SpringWorks obtained rights to nirogacestat from Pfizer as part of a broader collaboration involving nirogacestat and other assets. The transaction gave SpringWorks development and commercialization rights while preserving Pfizer’s economic participation through potential milestone payments and royalties.[5]
The license structure affects operating leverage. Product revenue does not translate directly into profit because SpringWorks must fund:
- Manufacturing and commercial supply.
- Specialty-pharmacy distribution.
- Patient-support programs.
- Medical-affairs and pharmacovigilance activities.
- Clinical studies and regulatory commitments.
- Royalties and milestone obligations under the license.
The later corporate ownership and strategic-partner structure should be reviewed separately from the underlying drug economics because a change in corporate control does not necessarily change patent ownership, royalty rates, or regulatory obligations.
What generic launch scenarios exist for Ogsiveo?
Base case
Ogsiveo maintains orphan exclusivity through 2030, with patent protection or litigation delaying meaningful generic entry beyond the orphan period. Revenue grows through patient identification and international expansion before declining gradually after loss of exclusivity.
Downside case
Payer step edits, adverse-event discontinuations, or a competing therapy reduce treatment persistence. Revenue peaks earlier and declines before patent expiry.
Upside case
Confirmatory data support the accelerated approval, international approvals expand access, and additional gamma-secretase-sensitive indications increase the treated population. Revenue exceeds the core desmoid-tumor opportunity.
Accelerated generic case
An ANDA filer defeats key patents or reaches a settlement permitting an earlier launch. Because the patient population is small, price erosion may be less severe than for mass-market drugs, but the branded product could lose a disproportionate share of new starts.
How strong is the nirogacestat patent estate?
The estate is commercially strong through the end of the decade because regulatory exclusivity, orphan status, specialized distribution, and a concentrated prescriber base reinforce one another. Patent strength is harder to assess from the molecule alone.
The most defensible claims are likely those tied to the approved clinical use and specific pharmaceutical forms, provided the asserted claims have adequate written description and nonobviousness support. Broad method-of-use claims face greater validity risk if prior art disclosed gamma-secretase inhibition or related Notch-mediated tumor treatment.
The practical barrier to entry is therefore a layered system:
- FDA orphan exclusivity through 2030.
- Orange Book-listed patent protection.
- Specialized clinical evidence.
- Limited patient volume for a potential generic entrant.
- Manufacturing and quality requirements for the hydrobromide product.
- Payer and specialty-pharmacy infrastructure.
Key Takeaways
- Nirogacestat hydrobromide is the active ingredient in Ogsiveo, approved for adults with progressing desmoid tumors.
- FDA approval occurred on November 27, 2023, under the accelerated approval pathway.
- Orphan-drug exclusivity is expected through November 27, 2030.
- SpringWorks converted Ogsiveo from a late-2023 launch into a more than $200 million annual product by 2024.
- The commercial opportunity is limited by disease rarity but supported by premium pricing, chronic treatment, and limited direct competition.
- The product has no biosimilar risk because it is a small-molecule drug.
- Generic risk will center on ANDA filings, Paragraph IV litigation, formulation patents, method-of-use claims, and post-2030 orphan-exclusivity timing.
- Safety, especially diarrhea and ovarian dysfunction, is the main commercial limitation.
- The highest-value catalysts are confirmatory regulatory success, international approvals, broader indications, and sustained treatment persistence.
FAQs About Nirogacestat Hydrobromide
What is the estimated annual price of Ogsiveo?
Ogsiveo is a specialty oncology product with an annual treatment cost in the high five-figure to low six-figure range before rebates and discounts. Net realized price depends on payer mix, patient assistance, government discounts, and treatment duration.
Is Ogsiveo chemotherapy?
No. Ogsiveo is an oral targeted therapy and gamma-secretase inhibitor. It is pharmacologically distinct from cytotoxic chemotherapy such as doxorubicin-based regimens.
Can nirogacestat be used for familial adenomatous polyposis?
Ogsiveo’s FDA-approved indication is progressing desmoid tumors requiring systemic treatment. Use in familial adenomatous polyposis or other tumors is not covered by the approved label unless separately supported by regulatory approval.
What is the main manufacturing barrier for nirogacestat?
The principal barriers are production of a consistent hydrobromide active pharmaceutical ingredient, control of solid-state characteristics, tablet quality, regulatory validation, and reliable specialty-pharmacy supply. These barriers are meaningful but generally less difficult than biologic manufacturing.
What event could most materially change the valuation of Ogsiveo?
A confirmatory-trial outcome or regulatory decision would have the largest direct impact. A successful result would support continued approval and expansion, while an adverse result could affect labeling, payer coverage, and long-term revenue expectations.
References
- U.S. Food and Drug Administration. (2023). Ogsiveo (nirogacestat) prescribing information.
- SpringWorks Therapeutics, Inc. (2025). Annual report on Form 10-K for fiscal year ended December 31, 2024. U.S. Securities and Exchange Commission.
- U.S. Food and Drug Administration. (2024). Orphan drug designation and exclusivity.
- U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
- SpringWorks Therapeutics, Inc. (2017). License agreement with Pfizer for nirogacestat and mirdametinib.
